debt_leverage_profile
Near-zero debt; Viking holds ~$900M+ cash with no material long-term debt, making 20bps rate shift immaterial to interest expense
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; cash-rich, debt-free balance sheet means rate increases slightly boost interest income, not a liability risk
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Dependence on single-source CMOs (likely Asian API manufacturers); China/India pharma API export restrictions are primary chokepoints
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue clinical-stage company with no international commercial revenue; currency devaluation exposure is effectively zero currently
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in US (San Diego HQ); no commercial international revenue markets; minimal FX exposure
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on contract manufacturers (e.g., PolyPeptide or similar CMOs) for VK2735/VK0214 peptide synthesis; non-substitutable short-term
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; primary model is drug development toward licensing/partnership or self-commercialization, not SaaS/cloud-dependent
Inferred
Agent_Inference
business_model_type_secondary
Potential partnership/licensing revenue model as secondary upon Phase 3 success; cloud termination would disrupt operations minimally
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; Viking uses standard CRO/CMO contracts with moderate switching friction but no proprietary platform lock-in
Inferred
Agent_Inference
howey_test_risk_index
Equity shares fund drug R&D with profit expectation from management efforts; standard public equity, Howey risk is low/not a security concern
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; clinical trial data handled under ICH GCP frameworks; no consumer data monetization
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; small-cap clinical-stage company with no marketed products or dominant market position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently ~0% recurring commercial revenue; 100% transactional/milestone-based (grants, future licensing); pre-revenue stage
Inferred
Agent_Inference
monetization_vector
Future monetization via drug sales (GLP-1/thyroid programs) or upfront+milestone licensing deals with large pharma partners
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; GLP-1 obesity market pricing benchmark ~$900-$1,300/month (Wegovy); VK2735 must price competitively or at discount
Inferred
Agent_Inference
pricing_power_rating
Moderate-high potential if VK2735 shows superior efficacy/tolerability vs. semaglutide; differentiation drives pricing power in obesity market
Inferred
Agent_Inference
target_gross_margin_bracket
Branded pharma gross margins typically 80-90%; Viking's target bracket ~80-85% post-commercialization if self-commercializing
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; prescription drug model requires ongoing Rx; patient adherence/persistence is the relevant retention metric
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth would be sublinear to headcount; commercialization via partner or lean sales force; R&D headcount ~70 FTEs currently
Inferred
Agent_Inference
marginal_cost_of_growth
Post-approval, marginal cost of growth driven by CMO scale-up and sales force, not proportional headcount; highly scalable if partnered
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Viking has no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics depend on DTC/physician detailing spend; GLP-1 market is large enough to absorb scale without CAC collapse
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; pharmaceutical efficacy/safety data accumulation provides weak data moat but not a true network effect
Inferred
Agent_Inference
asset_efficiency_ratio
-50.2% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate; obesity/metabolic disease drugs face some discretionary pressure but chronic disease treatment has recession-resistant demand
Inferred
Agent_Inference
customer_segment_primary
Future patients: adults with obesity/overweight (BMI ≥27) seeking GLP-1 receptor agonist therapy; massive addressable population
Inferred
Agent_Inference
customer_segment_secondary
Potential pharma licensing partners (large-cap pharma) representing concentrated deal risk; one partnership could dominate revenue
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated to clinical trials (Phase 2/3 for VK2735, VK0214); no legacy infrastructure; all spend is forward-looking R&D investment
Inferred
Agent_Inference
sec_cik
0001607678
High
SEC-EDGAR
ticker
VKTX
High
SEC-EDGAR